{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:25:13Z","timestamp":1769761513697,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010336","name":"Fundaci\u00f3 Privada Daniel Bravo Andreu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Early Human Development"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.earlhumdev.2019.104851","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:37:08Z","timestamp":1570556228000},"page":"104851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Treating neonatal spinal muscular atrophy: A 21st century success story?"],"prefix":"10.1016","volume":"138","author":[{"given":"Eduardo F.","family":"Tizzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.earlhumdev.2019.104851_bb0005","doi-asserted-by":"crossref","unstructured":"Tizzano EF. Advanced therapies in rare diseases: the example of spinal muscular atrophy. Med Clin (Barc). 2018 Oct 12;151(7):275\u2013277. doi:https:\/\/doi.org\/10.1016\/j.medcli.2018.03.001. Epub 2018 Apr 21. English, Spanish. PubMed PMID: 29685310.","DOI":"10.1016\/j.medcle.2018.03.025"},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.earlhumdev.2019.104851_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nmd.2008.10.004","article-title":"Ramblings in the history of spinal muscular atrophy","volume":"19","author":"Dubowitz","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0025","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"ENDEAR study group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26-28 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.earlhumdev.2019.104851_bb0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/gt.2017.52","article-title":"The clinical landscape for SMA in a new therapeutic era","volume":"24","author":"Talbot","year":"2017","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.earlhumdev.2019.104851_bb0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/64.3.215","article-title":"Implication of fetal SMN2 expression in type I SMA pathogenesis: protection or pathological gain of function?","volume":"64","author":"Soler-Botija","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00439-008-0598-1","article-title":"Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene","volume":"125","author":"Al\u00edas","year":"2009","journal-title":"Hum. Genet."},{"issue":"11","key":"10.1016\/j.earlhumdev.2019.104851_bb0070","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2,834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.earlhumdev.2019.104851_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nmd.2011.03.009","article-title":"Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings","volume":"21","author":"Bernal","year":"2011","journal-title":"Neuromuscul. Disord."},{"issue":"6","key":"10.1016\/j.earlhumdev.2019.104851_bb0085","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","article-title":"Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention","volume":"22","author":"Tizzano","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"12","key":"10.1016\/j.earlhumdev.2019.104851_bb0090","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","article-title":"The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy","volume":"7","author":"Burlet","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0095","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1038\/srep11696","article-title":"Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons","volume":"5","author":"Boza-Mor\u00e1n","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.earlhumdev.2019.104851_bb0100","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1172\/JCI121658","article-title":"Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain","volume":"128","author":"Sumner","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.earlhumdev.2019.104851_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/joa.12083","article-title":"Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?","volume":"224","author":"Shababi","year":"2014","journal-title":"J. Anat."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0115","doi-asserted-by":"crossref","unstructured":"Mendon\u00e7a RH, Rocha AJ, Lozano-Arango A, Diaz AB, Castiglioni C, Silva AMS, Reed UC, Kulikowski L, Paramonov I, Cusc\u00f3 I, Tizzano EF, Zanoteli E. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol. 2019 Jul 13. doi: https:\/\/doi.org\/10.1002\/ana.25549. [Epub ahead of print] PubMed PMID: 31301241.","DOI":"10.1002\/ana.25549"},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"7367","key":"10.1016\/j.earlhumdev.2019.104851_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"6197","key":"10.1016\/j.earlhumdev.2019.104851_bb0130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0135","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"CHERISH study group. Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.earlhumdev.2019.104851_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0145","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","article-title":"Spinal muscular atrophy: a changing phenotype beyond the clinical trials","volume":"27","author":"Tizzano","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2017.04.1218","article-title":"Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): interim results from the NURTURE study","volume":"21","author":"Bertini","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0155","doi-asserted-by":"crossref","unstructured":"De Vivo, D.; Bertini, E.; Swoboda, K.J.; et al., Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study Neuromusc DIsord (in press) DOI: https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","DOI":"10.1016\/j.nmd.2019.09.007"},{"issue":"2","key":"10.1016\/j.earlhumdev.2019.104851_bb0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0165","doi-asserted-by":"crossref","unstructured":"Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW, McColly M, Lehman KJ, Church K, Sproule DM, Nagendran S, Menier M, Feltner DE, Wells C, Kissel JT, Al-Zaidy S, Mendell J. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose Gene replacement therapy. Pediatr Neurol. 2019 May 13. pii: S0887 8994(19)30280\u20132.","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"issue":"2","key":"10.1016\/j.earlhumdev.2019.104851_bb0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.earlhumdev.2019.104851_bb0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.earlhumdev.2019.104851_bb0185","doi-asserted-by":"crossref","unstructured":"Serra-Juhe C, Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur. J. Hum. Genet. 2019 May 3. doi:https:\/\/doi.org\/10.1038\/s41431-019-0415-4. [Epub ahead of print] Review. PubMed PMID: 31053787.","DOI":"10.1038\/s41431-019-0415-4"},{"issue":"5","key":"10.1016\/j.earlhumdev.2019.104851_bb0190","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Early Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378219304918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378219304918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T01:57:31Z","timestamp":1759888651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378378219304918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"alternative-id":["S0378378219304918"],"URL":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2019.104851","relation":{},"ISSN":["0378-3782"],"issn-type":[{"value":"0378-3782","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating neonatal spinal muscular atrophy: A 21st century success story?","name":"articletitle","label":"Article Title"},{"value":"Early Human Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2019.104851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104851"}}